Miguel Mujica Baella, MD
Hospitalist · Miami, FLNPI 1962611673
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 4 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. GSK accounts for 76.6% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for hospitalist clinicians in FL, where the typical reported total is $187.
Across 4 payments — averaging $26.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$81
- Baxter Healthcare$25
Across 312 payments — averaging $5868.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Chiesi USA, Inc.$973K
- Eli Lilly$439K
- Teva Pharmaceuticals USA, Inc.$275K
- Merck$99K
- Astrazeneca UK Limited$26K
- Genentech, Inc.$19K
- plus $353 from 1 others
What the payments were for
- Food & beverage$106100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 3 | $81 |
| Baxter Healthcare | 1 | $25 |
How this compares
$106 in reported general payments places this provider in the 35th percentile of 1,570 hospitalist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 24 | $14,355 |
| Budesonide | 24 | $3,699 |
| Memantine Hcl | 32 | $1,706 |
| Levetiracetam | 28 | $1,491 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 11 | $1,324 |
| Duloxetine Hcl | 13 | $687 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 12 | $413 |
| Atorvastatin Calcium | 35 | $378 |
| Chlorthalidone | 15 | $368 |
| Gabapentin | 14 | $307 |
| Verapamil ErVerapamil Hcl | 13 | $297 |
| Metoprolol Succinate | 19 | $285 |
| Bupropion Hcl | 12 | $272 |
| Losartan Potassium | 28 | $265 |
| Clonazepam | 54 | $225 |
Paid to pharmacies, not to this prescriber.
Other hospitalist in Miami
- Murray EpsteinMiami$370K
- Francisco Perez LoretoMiami$17K
- Alexangel SantanaMiami$7K
- Yasser AsmarMiami$7K
- Seth BleicherMiami$6K
- Daniel LopezMiami$4K
- Tina SanjarMiami$3K
- Oliver AbelaFort Myers$77K
- Joshua LenchusFort Lauderdale$73K
- Tuncay TaskesenThe Villages$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.